Amgen Inc. (AMGN)
AMGNNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$463.46
-1.78 (-0.38%) today
Regular session, Nov 10, 1:19 PM ET
- Market cap
- $250.69bn
- P/E
- 20.0
- EPS, last 4 quarters
- $23.18
- Dividend yield
- 2.17%
- Day range
- $459.72 to $468.79
- 52-week range
- $312.39 to $483.99
- Average volume
- 2.89m
- Previous close
- $465.23
Analysts
25 coveringHold9 buy, 15 hold, 1 sell
Targets a year out average $449.68, -3.0% from here
Earnings
next estimate $5.55Next report
Dec 2025
+11.1%
Mar 2026
+8.9%
Jun 2026
+12.3%
Sep 2026
+12.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $9.87bn | $8.62bn | $10.05bn | $10.37bn |
| Gross profit | $6.89bn | $5.87bn | $7.24bn | $7.58bn |
| Operating income | $2.72bn | $2.67bn | $3.51bn | $3.71bn |
| Net income | $1.33bn | $1.82bn | $2.38bn | $3.86bn |
Last four quarters: revenue $38.90bn, margin 24.1%, free cash flow $9.58bn
News
8 latest- Amgen Highlights Repatha's Cost-Effectiveness, Long-Term Cardiovascular Benefits RTTNews · 11 hours ago
- Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending StockZacks · 1 day ago
- The Top 5 Biotech Stocks I'd Buy Right Now Without Any HesitationThe Motley Fool · 1 day ago
- After the Midterm Rally, the Dow Is on Track to Beat the Nasdaq for the First Time Since 2022. Here's What History Says Could Come Next.The Motley Fool · 4 days ago
- Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?The Motley Fool · 5 days ago
- Amgen's Real-World Data Shows Repatha Outperforms Ezetimibe For Heart Disease RTTNews · 5 days ago
- Upcoming Dividend Run For AMGN?BNK Invest · 5 days ago
- Amgen (AMGN) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
The company
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S . headquarters in Thousand Oaks, California , and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions. Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- amgen.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.